截至2025年8月22日收盘，昂利康股价报50.56元，较前一交易日下跌1.56%。当日成交额达4.33亿元， 换手率为4.64%。 昂利康属于化学制药板块，公司主营业务为医药产品的研发、生产和销售。作为创新药概念股，公司产 品涵盖抗感染类、心血管类、消化系统类等多个治疗领域。 近期创新药行业迎来多项政策支持。国家医保局与卫健委7月初印发《支持创新药高质量发展的若干措 施》，提出增设商业健康保险创新药品目录，支持创新药进入医保目录和商业保险创新药品目录。此 外，创新药出海也取得进展，多家药企与跨国药企达成合作协议。 资金流向方面，8月22日昂利康主力资金净流入365.83万元，近五日主力资金净流入1.35亿元。 风险提示：股市有风险，投资需谨慎。 ...

Group 1 - On August 8, the stock price of Anglikang closed at 54.34 yuan, down 1.41 yuan or 2.53% from the previous trading day [1] - The opening price on the same day was 55.64 yuan, with a highest point of 57.25 yuan and a lowest point of 54.06 yuan, with a trading volume of 140,753 hands and a transaction amount of 777 million yuan [1] - Around 10:12 AM on August 8, Anglikang's stock price experienced a rapid rebound, increasing over 2% within 5 minutes, rising from 55.59 yuan to 56.1 yuan, with a transaction amount of 199 million yuan during this period [1] Group 2 - Anglikang operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical products [1] - The company's product range includes treatments for various fields such as anti-infection, cardiovascular, and digestive systems [1] Group 3 - On August 8, the net outflow of main funds was 49.57 million yuan, with a cumulative net outflow of 296 million yuan over the past five trading days [1]